NVN Liquidation (NVN Liquidation) Interest Expense : $-1.60 Mil (TTM As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NVN Liquidation's interest expense for the three months ended in Mar. 2023 was $ -0.28 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.60 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NVN Liquidation's Operating Income for the three months ended in Mar. 2023 was $ -13.47 Mil. NVN Liquidation's Interest Expense for the three months ended in Mar. 2023 was $ -0.28 Mil. NVN Liquidation did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NVN Liquidation Interest Expense Historical Data

The historical data trend for NVN Liquidation's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NVN Liquidation Interest Expense Chart

NVN Liquidation Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-1.05

-1.45

NVN Liquidation Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Interest Expense	Get a 7-Day Free Trial															-0.13	-0.61	-0.64	-0.08	-0.28

NVN Liquidation Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60 Mil.

NVN Liquidation (OTCPK:NOVNQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NVN Liquidation's Interest Expense for the three months ended in Mar. 2023 was $-0.28 Mil. Its Operating Income for the three months ended in Mar. 2023 was $-13.47 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2023 was $3.39 Mil.

NVN Liquidation's Interest Coverage for the quarter that ended in Mar. 2023 is calculated as

NVN Liquidation did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

NVN Liquidation (NVN Liquidation) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.

Executives

Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman	director	9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour	director	C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay	officer: VP, Finance & Corp. Controller	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John	officer: EVP, Chief Operating Officer	C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky	director	TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin	director	C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram	director	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer	director	7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak	officer: Chief Accounting Officer	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust	10 percent owner	100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker	10 percent owner	100 SAS CAMPUS DRIVE, CARY NC 27513